[go: up one dir, main page]

WO2002036769A3 - Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof - Google Patents

Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof Download PDF

Info

Publication number
WO2002036769A3
WO2002036769A3 PCT/EP2001/012495 EP0112495W WO0236769A3 WO 2002036769 A3 WO2002036769 A3 WO 2002036769A3 EP 0112495 W EP0112495 W EP 0112495W WO 0236769 A3 WO0236769 A3 WO 0236769A3
Authority
WO
WIPO (PCT)
Prior art keywords
production
methods
nucleic acids
acids encoding
chimeric polypeptides
Prior art date
Application number
PCT/EP2001/012495
Other languages
French (fr)
Other versions
WO2002036769A2 (en
Inventor
Frank Dicker
Dirk Moritz
Gerd Maass
Original Assignee
Hoffmann La Roche
Frank Dicker
Dirk Moritz
Gerd Maass
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Frank Dicker, Dirk Moritz, Gerd Maass filed Critical Hoffmann La Roche
Priority to AU2002221780A priority Critical patent/AU2002221780A1/en
Publication of WO2002036769A2 publication Critical patent/WO2002036769A2/en
Publication of WO2002036769A3 publication Critical patent/WO2002036769A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A nucleic acid encoding a CD40/CD40L chimeric polypeptide comprising nucleic acid fragments encoding i) the signaling domain of CD40 and downstream thereof, ii) a transmembrane domain of a type II receptor and downstream thereof iii) the binding and trimerization domain of CD40L, is useful as a gene therapy agent for the local treatment of solid tumors.
PCT/EP2001/012495 2000-10-31 2001-10-29 Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof WO2002036769A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002221780A AU2002221780A1 (en) 2000-10-31 2001-10-29 Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00123721 2000-10-31
EP00123721.3 2000-10-31

Publications (2)

Publication Number Publication Date
WO2002036769A2 WO2002036769A2 (en) 2002-05-10
WO2002036769A3 true WO2002036769A3 (en) 2003-01-30

Family

ID=8170257

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/012495 WO2002036769A2 (en) 2000-10-31 2001-10-29 Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof

Country Status (2)

Country Link
AU (1) AU2002221780A1 (en)
WO (1) WO2002036769A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2739073C2 (en) * 2014-04-07 2020-12-21 Локон Фарма Аб New medical agents and use thereof

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ755300A0 (en) 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
EP2933334B1 (en) 2003-02-18 2019-09-18 Baylor College of Medicine Induced activation in dendritic cells
EP2517723B1 (en) 2006-09-18 2019-11-06 The Board of Trustees of The University of Arkansas Compositions and methods of enhancing immune responses
AU2007310946B2 (en) 2006-10-19 2014-06-05 Baylor College Of Medicine Generating an immune response by inducing CD40 and pattern recognition receptors
EP2214840B1 (en) 2007-10-30 2015-05-06 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
CA3156538C (en) 2007-11-01 2023-12-12 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
DK2331680T3 (en) 2008-09-22 2017-08-21 Baylor College Medicine Methods and Compositions for Generating an Immune Response by Induction of CD-40 as well as Pattern Recognition Receptor Adapters
CN102811734B (en) 2010-01-21 2016-02-10 阿肯色大学评议会 Vaccine vectors and methods for enhancing immune response
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
JP5746333B2 (en) 2010-06-09 2015-07-08 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー Vaccines and methods for reducing Campylobacter infection
EP3610887B8 (en) 2013-02-14 2024-01-24 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
SG11201506974XA (en) 2013-03-14 2015-10-29 Bellicum Pharmaceuticals Inc Methods for controlling t cell proliferation
KR102239207B1 (en) 2013-03-15 2021-04-09 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 Compositions and methods of enhancing immune responses to enteric pathogens
JP6467406B2 (en) 2013-06-05 2019-02-13 ベリカム ファーマシューティカルズ， インコーポレイテッド Methods for inducing partial apoptosis using caspase polypeptides
CN106132423B (en) 2014-02-14 2020-07-31 贝里坤制药股份有限公司 Methods of activating T cells with inducible chimeric polypeptides
CA2959168A1 (en) 2014-09-02 2016-03-10 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
JP6718444B2 (en) 2014-11-03 2020-07-08 アカデミッシュ ザイケンホイス レイデン （エイチ．オー．ディー．エヌ． エルユーエムシー） T cell receptors directed against Bob1 and uses thereof
SG11201809686SA (en) 2016-05-03 2018-11-29 Univ Arkansas Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
US11564944B2 (en) 2016-11-21 2023-01-31 Nant Holdings Ip, Llc Fractal combination therapy
GB201720949D0 (en) 2017-12-15 2018-01-31 Autolus Ltd Cell
CA3098498A1 (en) * 2018-06-14 2019-12-19 Nantbio, Inc. Tnf-type receptor-ligand fusion proteins and methods
US20210369825A1 (en) * 2018-10-05 2021-12-02 Nantcell, Inc. Cd40 and cd40l combo in an adv vaccine vehicle
AU2020315796A1 (en) * 2019-07-19 2022-02-24 Memorial Hospital For Cancer And Allied Diseases Fusion polypeptide for immunotherapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008207A1 (en) * 1991-10-25 1993-04-29 Immunex Corporation Novel cytokine
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
WO1998026061A2 (en) * 1996-12-09 1998-06-18 University Of California Expression vectors containing accessory molecule ligand genes and their use for immunomodulation and treatment of malignancies and autoimmune disease
WO2000063395A1 (en) * 1999-04-16 2000-10-26 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008207A1 (en) * 1991-10-25 1993-04-29 Immunex Corporation Novel cytokine
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
WO1998026061A2 (en) * 1996-12-09 1998-06-18 University Of California Expression vectors containing accessory molecule ligand genes and their use for immunomodulation and treatment of malignancies and autoimmune disease
WO2000063395A1 (en) * 1999-04-16 2000-10-26 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2739073C2 (en) * 2014-04-07 2020-12-21 Локон Фарма Аб New medical agents and use thereof

Also Published As

Publication number Publication date
WO2002036769A2 (en) 2002-05-10
AU2002221780A1 (en) 2002-05-15

Similar Documents

Publication Publication Date Title
WO2002036769A3 (en) Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
WO2001072957A3 (en) Fibroblast growth factor-like molecules and uses thereof
EP1482040A3 (en) Nl3 tie receptor tyrosine kinase ligand homologues
WO2002024891A3 (en) B7-like molecules and uses thereof
WO2002008285A3 (en) Il-17 molecules and uses thereof
AU2175597A (en) Modulators of tnf receptor associated factor (traf), their preparation and use
IL140938A (en) Dna sequences encoding polypeptides capable of binding to ldcam, polypeptides encoded by them, fusion proteins comprising the polypeptides and a process for the preparation of the polypeptides
WO2001092308A3 (en) Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
WO2000018914A3 (en) Novel dkr polypeptides
IL144952A0 (en) Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
WO2003020932A1 (en) Novel secretory proteins and dna thereof
WO2001068854A3 (en) Fibroblast growth factor-like molecules and uses thereof
WO2001055178A3 (en) Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer
AU8881201A (en) Tnf receptor-like molecules and uses thereof
WO2001005825A3 (en) Nucleic acid sequences encoding putative angiopoietin proteins
WO2001068859A3 (en) Il-17 receptor like molecules and uses thereof
WO2003008446A1 (en) Polypeptides relating to signal transfer of advanced glycation end product receptor
WO2001068705A3 (en) Il-17 receptor like molecules and uses thereof
MXPA01006006A (en) Cytokine receptor chain.
WO2001042474A3 (en) Interferon-like molecules and uses thereof
WO2002062954A3 (en) Antisense modulation of casein kinase 2-beta expression
WO2001019861A3 (en) Apo-2 receptor antibodies
WO2002016611A3 (en) Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
WO2002062818A3 (en) Antisense modulation of casein kinase 2-alpha expression
WO2001059120A3 (en) Il-17 like molecules and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP